Everything below concerns Melanotan II. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Bezitramide is an opioid analgesic. Bezitramide itself is a prodrug which is readily hydrolyzed in the gastrointestinal tract to its active metabolite, despropionyl-bezitramide. Bezitramide was discovered at Janssen Pharmaceutica in 1961. It is most commonly marketed under the trade name Burgodin. The drug was pulled from the shelves in the Netherlands in 2004 after fatal overdose cases, including one where a five-year-old child took one tablet from his mother's purse, ate it, and promptly died. Bezitramide is regulated much the same as morphine in all known jurisdictions and is a Schedule II substance under the United States' Controlled Substances Act of 1970, with an ACSCN of 9800 and zero annual manufacturing quota. However, as of May 2021, it has never been marketed in the United States.
Initial clinical trial results with IgG4 PD1 antibody nivolumab were published in 2010. It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. A 2016 clinical trial for non-small cell lung cancer failed to meet its primary endpoint for treatment in the first-line setting, but is FDA-approved in subsequent lines of therapy. Pembrolizumab (Keytruda) is another PD1 inhibitor that was approved by the FDA in 2014. Pembrolizumab is approved to treat melanoma and lung cancer. Antibody BGB-A317 is a PD-1 inhibitor (designed to not bind Fc gamma receptor I) in early clinical trials.
A study skin is a taxidermic zoological specimen prepared in a minimalistic fashion that is concerned only with preserving the animal's skin, not the shape of the animal's body. As the name implies, study skins are used for scientific study (research), and are housed mainly by museums. A study skin's sole purpose is to preserve data, not to replicate an animal in a lifelike state. Museums keep large collections of study skins in order to conduct comparisons of physical characteristics to other study skins of the same species. Study skins are also kept because DNA can be extracted from them when needed at any point in time. A study skin's preparation is extremely basic. After the animal is skinned, fat is methodically scraped off the underside of the hide. The underside of the hide is then rubbed with borax or cedar dust to help it dry faster. The animal is then stuffed with cotton and sewn up. Mammals are laid flat on their belly. Birds are prepared lying on their back. Study skins are dried in these positions to keep the end product as slender and streamlined as possible so large numbers of specimens can be stored side-by-side in flat file drawers, while occupying a minimum amount of space. Since study skins are not prepared with aesthetics in mind they do not have imitation eyes like other taxidermy, and their cotton filling is visible in their eye openings.
Sources: en.wikipedia.org
Circumcision is one of the oldest surgical procedures in human history, and remains a highly emotional and controversial issue. Many societies hold a wide-ranging perspectives and different cultural, ethical, or social views on circumcision. In some cultures, males are generally required to be circumcised shortly after birth, during childhood or around puberty as part of a rite of passage.
Due to the shorter distance to be travelled in the United Kingdom, the need for refrigeration was limited to specialised goods, which could in express-train format - mostly run overnight to avoid delays from passenger traffic - be transported in suitable timescales of less than a day from the area of production to processing, or onwards to the point of consumer consumption. Hence, whilst similar shipping requirements for cattle, fish, fruit, and farm-fresh produce existed, the need for refrigeration was often minimized by using non-stop express train service to the required destination. For example, the London Midland and Scottish Railway ran specialized express trains from meat producer hubs in Scotland and the North of England to the Smithfield Meat Market in London, with a dedicated goods station located below ground level directly into the market's slaughtering house. The LMS and the LNER also ran express fish trains from Fleetwood and Grimsby to Broad Street to access Billingsgate Fish Market. The big four railway companies standardized their ice-chilled wagons within their own networks, which were built with more insulation, further minimizing the need for onboard mechanical refrigeration. The Great Western Railway designed and built their own Mica A (ventilated) and Mica B (Non-ventilated) vans for such express produce trains, with ice supplied by the original product producer from their own plant.
=== Graphene quantum dots === A graphene quantum dot (GQD) is a graphene fragment with a size less than 100 nm. The properties of GQDs are different from bulk graphene due to the quantum confinement effects which only become apparent when the size is smaller than 100 nm.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.